RecruitingNCT04598750

The Neonatal Hemorrhagic Risk Assessment in Thrombocytopenia

Studying Fetal and neonatal alloimmune thrombocytopenia

Last synced from ClinicalTrials.gov May 9, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Karolinska Institutet
Principal Investigator: Emöke Deschmann, MD, PhD
Karolinska Institutet
Enrollment: 250 enrolled
Eligibility: All sexes
Timeline: 2021 – 2025

Study locations (8)

Boston Children's Hospital, Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Intermountain Medical Center, Murray, Utah, United States
Utah Valley Hospital, Provo, Utah, United States
Amsterdam University Medical Centre, Amsterdam, Netherlands
Leiden University Medical Center, Leiden, Netherlands
Karolinska University Hospital Huddinge campus, Huddinge, Sweden
Karolinska University Hospital Solna campus, Astrid Lindgren Children's Hospital, Stockholm, Sweden

Collaborators

Karolinska University Hospital · National Heart, Lung, and Blood Institute (NHLBI) · Boston Children's Hospital · Harvard Medical School (HMS and HSDM) · Region Stockholm · The Swedish Society of Medicine

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04598750 on ClinicalTrials.gov

Other trials for Fetal and neonatal alloimmune thrombocytopenia

Additional recruiting or active studies for the same condition.

See all trials for Fetal and neonatal alloimmune thrombocytopenia →

← Back to all trials